Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | RARG | P13631 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL689927 | 0.84 | HPGD (0.69) | CES2CES1ALDH1A1HPGDKDM4E | |
| SCHEMBL20591211 | 0.84 | HPGD (0.70) | SIRT2SIRT1SIRT3CES2CES1 | |
| SCHEMBL5631937 | 0.82 | RXRA (0.48) | ALDH1A1HPGDKDM4ERARBRARG | |
| SCHEMBL3281214 | 0.82 | LMNA (0.52) | SIRT2SIRT1SIRT3ALDH1A1HPGD | |
| SCHEMBL15220063 | 0.82 | TSHR (0.67) | CES2CES1ALDH1A1HPGDKDM4E | |
| SCHEMBL15220060 | 0.82 | TSHR (0.67) | CES2CES1ALDH1A1HPGDKDM4E | |
| SCHEMBL71112 | 0.82 | TSHR (0.67) | CES2CES1ALDH1A1HPGDKDM4E | |
| Beta-Naphtoic Acid SCHEMBL9008562 | 0.80 | CES2 (0.65) | CES2CES1ALDH1A1HPGDKDM4E | |
| Beta-Naphtoic Acid SCHEMBL29628843 | 0.80 | CES2 (0.71) | CES2CES1ALDH1A1HPGDKDM4E | |
| Beta-Naphtoic Acid SCHEMBL98296 | 0.80 | CES2 (0.71) | CES2CES1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| CN-1048239-C | Naphthalene deriv. | TEIJIN LTD (JP) | 2000-01-12 | — | — | CN | disclosed |
| EP-0763523-B1 | NAPHTHALENE DERIVATIVE | TEIJIN LTD (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5945450-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1999-08-31 | — | — | US | disclosed |
| CN-1153511-A | Naphthalene deriv. | TEIJIN LTD (JP) | 1997-07-02 | — | — | CN | disclosed |
| EP-0763523-A1 | NAPHTHALENE DERIVATIVE | TEIJIN LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | SIRT2 1233/4885SIRT1 1272/4885SIRT3 1329/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | SIRT2 1004/4885SIRT1 1273/4885SIRT3 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.